MX2011012513A - Metodos para tratar cancer y estados no neoplasicos. - Google Patents
Metodos para tratar cancer y estados no neoplasicos.Info
- Publication number
- MX2011012513A MX2011012513A MX2011012513A MX2011012513A MX2011012513A MX 2011012513 A MX2011012513 A MX 2011012513A MX 2011012513 A MX2011012513 A MX 2011012513A MX 2011012513 A MX2011012513 A MX 2011012513A MX 2011012513 A MX2011012513 A MX 2011012513A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- methods
- viral
- production
- treating cancer
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000001613 neoplastic effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 9
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 108020005202 Viral DNA Proteins 0.000 abstract 2
- 108010067390 Viral Proteins Proteins 0.000 abstract 2
- 108020000999 Viral RNA Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000029812 viral genome replication Effects 0.000 abstract 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 238000011374 additional therapy Methods 0.000 abstract 1
- 102000058223 human VEGFA Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se describen compuestos que inhiben selectivamente la producción patológica del factor de crecimiento endotelial vascular humano (VEGF) y las composiciones que contienen tales compuestos. Se describen compuestos que inhiben la replicación viral o la producción de RNA o DNA viral o proteína viral, y las composiciones que contienen tales compuestos. También se describen métodos para disminuir el VEGF empleando tales compuestos y los métodos para tratar cáncer y estados no neoplásicos que incluyen la administración de tales compuestos. Además están descritos los métodos para inhibir la replicación viral o la reproducción de RNA o DNA viral o proteína viral empleando estos compuestos, y los métodos para tratar infecciones virales que incluyen la administración de tales compuestos. Los compuestos pueden ser administrados como terapia de un solo compuesto o en combinación con una o más terapias adicionales a un humano que necesite de estos tratamientos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18165309P | 2009-05-27 | 2009-05-27 | |
PCT/US2010/036467 WO2010138758A1 (en) | 2009-05-27 | 2010-05-27 | Methods for treating cancer and non-neoplastic conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2011012513A true MX2011012513A (es) | 2012-02-13 |
MX348817B MX348817B (es) | 2017-06-30 |
Family
ID=43223094
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020005345A MX2020005345A (es) | 2009-05-27 | 2010-05-27 | Un método para inhibir o reducir una infección viral por coronavirus. |
MX2011012513A MX348817B (es) | 2009-05-27 | 2010-05-27 | Metodos para tratar cancer y estados no neoplasicos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020005345A MX2020005345A (es) | 2009-05-27 | 2010-05-27 | Un método para inhibir o reducir una infección viral por coronavirus. |
Country Status (13)
Country | Link |
---|---|
US (5) | US9351964B2 (es) |
EP (2) | EP2434891B9 (es) |
JP (2) | JP5898067B2 (es) |
CN (2) | CN106167488A (es) |
AU (1) | AU2016208323B2 (es) |
CA (4) | CA3080983C (es) |
ES (1) | ES2826950T3 (es) |
HU (1) | HUE052510T2 (es) |
MX (2) | MX2020005345A (es) |
PL (1) | PL2434891T3 (es) |
PT (1) | PT2434891T (es) |
TW (2) | TWI671297B (es) |
WO (1) | WO2010138758A1 (es) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8551463B2 (en) | 2007-10-22 | 2013-10-08 | Living Proof, Inc. | Hair care compositions and methods of treating hair |
WO2010138758A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
US8697662B2 (en) | 2009-05-27 | 2014-04-15 | Ptc Therapeutics, Inc. | Methods for treating Kaposi sarcoma |
TW201100419A (en) | 2009-05-27 | 2011-01-01 | Ptc Therapeutics Inc | Processes for the preparation of substituted tetrahydro beta-carbolines |
US8703726B2 (en) | 2009-05-27 | 2014-04-22 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
FR2975600B1 (fr) * | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
EP3569598A1 (en) | 2011-11-17 | 2019-11-20 | Dana Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
CN103450196B (zh) * | 2012-05-29 | 2015-07-08 | 首都医科大学 | Agdv肽修饰的咔啉并六氢吡嗪-1,4-二酮、其制备方法、抗血栓作用和应用 |
BR112015004205B1 (pt) | 2012-08-28 | 2022-02-01 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidas, seu uso das mesmas como medicamentos para o tratamento da hepatite b, composição farmacêutica que as compreende e produto |
GB201303184D0 (en) * | 2013-02-22 | 2013-04-10 | Virttu Biolog Ltd | Treatment of cancer |
SI2961732T1 (sl) | 2013-02-28 | 2017-07-31 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B |
WO2014145751A2 (en) * | 2013-03-15 | 2014-09-18 | The Translational Genomics Research Institute | Targeted therapies for cancer |
EP2981536B1 (en) | 2013-04-03 | 2017-06-14 | Janssen Sciences Ireland UC | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
EP3004090B1 (en) * | 2013-05-28 | 2017-10-25 | Astrazeneca AB | Chemical compounds |
DK3024819T3 (en) | 2013-07-25 | 2018-06-06 | Janssen Sciences Ireland Uc | GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B |
TWI489307B (zh) * | 2013-09-06 | 2015-06-21 | Univ Nat Yang Ming | Evaluation method and system of blood brain barrier recovery curve |
WO2015059212A1 (en) * | 2013-10-23 | 2015-04-30 | Janssen R&D Ireland | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
EA035848B1 (ru) | 2014-02-06 | 2020-08-20 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b |
CA2952897A1 (en) * | 2014-06-27 | 2015-12-30 | Nogra Pharma Limited | Aryl receptor modulators and methods of making and using the same |
CN118005631A (zh) * | 2014-12-18 | 2024-05-10 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
MA41614A (fr) * | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
EA202192092A3 (ru) * | 2015-04-02 | 2022-03-31 | Ф. Хоффманн-Ля Рош Аг | Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение |
MX2017014163A (es) | 2015-05-06 | 2018-08-15 | Univ California | Moduladores de k-ras. |
MX2017016669A (es) | 2015-06-18 | 2018-04-13 | Cephalon Inc | Derivados de piperidina 1,4-sustituidos. |
US10919875B2 (en) | 2015-06-18 | 2021-02-16 | 89Bio Ltd | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
TWI771272B (zh) * | 2015-06-30 | 2022-07-21 | 美商伊格集團國際股份有限公司 | 克立咪唑(clemizole)化合物於預防及治療肝癌之用途 |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
DK3355884T3 (da) | 2015-10-01 | 2021-08-02 | Olema Pharmaceuticals Inc | Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler |
JP2019001715A (ja) * | 2015-10-30 | 2019-01-10 | 協和発酵キリン株式会社 | 三環性化合物 |
CN113717170A (zh) * | 2016-04-01 | 2021-11-30 | 里科瑞尔姆Ip控股有限责任公司 | 雌激素受体调节剂 |
JP2019511542A (ja) | 2016-04-15 | 2019-04-25 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カプシド集合阻害剤を含む組み合わせ及び方法 |
US10125135B2 (en) | 2016-04-20 | 2018-11-13 | Astrazeneca Ab | Chemical compounds |
WO2017210489A1 (en) | 2016-06-01 | 2017-12-07 | M3 Biotechnology, Inc. | Compounds |
CN109311876B (zh) * | 2016-06-16 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 杂芳基雌激素受体调节剂及其用途 |
US20180002344A1 (en) * | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
WO2018019793A1 (en) | 2016-07-25 | 2018-02-01 | Astrazeneca Ab | N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer |
US20190231718A1 (en) | 2016-10-11 | 2019-08-01 | Duke University | Treatment of breast cancer |
SG11201903182XA (en) | 2016-10-24 | 2019-05-30 | Astrazeneca Ab | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
WO2018115984A1 (en) | 2016-12-19 | 2018-06-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation |
WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
WO2018130123A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的五环类化合物及其应用 |
LT3494116T (lt) | 2017-01-30 | 2020-01-10 | Astrazeneca Ab | Estrogeno receptorių moduliatoriai |
US10195214B2 (en) | 2017-03-01 | 2019-02-05 | Corcept Therapeutics, Inc. | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
SG11201909570PA (en) | 2017-04-20 | 2019-11-28 | Univ California | K-ras modulators |
CN108864080B (zh) * | 2017-05-09 | 2021-10-15 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的四环类化合物及其应用 |
EP3664803A4 (en) | 2017-08-01 | 2021-05-05 | PTC Therapeutics, Inc. | DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS |
JP2019151631A (ja) * | 2018-03-02 | 2019-09-12 | 国立大学法人 岡山大学 | 植物病害防除剤及び植物病害の防除方法 |
MX2020009531A (es) | 2018-03-14 | 2020-10-05 | Janssen Sciences Ireland Unlimited Co | Regimen posologico del modulador del ensamblaje de la capside. |
WO2019199891A1 (en) | 2018-04-10 | 2019-10-17 | Duke University | Lasofoxifene treatment of breast cancer |
JP2021526792A (ja) | 2018-06-06 | 2021-10-11 | マサチューセッツ インスティテュート オブ テクノロジー | 真核細胞における翻訳のための環状rna |
HUE064542T2 (hu) | 2018-06-21 | 2024-03-28 | Hoffmann La Roche | A 3-((1R,3R)1(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9 -tetrahidro-2H-pirido[3,4-b]indol-2-il)-2,2-difluoropropán-1-ol tartarátsó szilárd formái, eljárás elõállításukra és rákos megbetegedések kezelésében történõ alkalmazási módszereik |
CR20210093A (es) * | 2018-08-03 | 2021-05-28 | Ptc Therapeutics Inc | Formas farmacéuticas orales biodisponibles |
EP3860996A4 (en) | 2018-10-02 | 2022-08-31 | Northwestern University | BETA-CARBOLINES AS POSITIVE ALLOSTERIC MODULATORS OF HUMAN SEROTONIN RECEPTOR 2C (5-HT2C) |
CN109400604B (zh) * | 2018-10-25 | 2021-09-03 | 河北科技大学 | 2,3,4,9-四氢-1H-吡啶并[3,4-b]吲哚类化合物及用途 |
MX2021008523A (es) | 2019-01-15 | 2021-11-12 | Ptc Therapeutics Inc | Metodo para tratar una leucemia mieloide aguda. |
AU2020223865A1 (en) | 2019-02-22 | 2021-07-15 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
JP2022532526A (ja) | 2019-05-06 | 2022-07-15 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Hbv感染又はhbv誘導性疾患の処置において有用なアミド誘導体 |
AU2020280105A1 (en) | 2019-05-22 | 2022-01-20 | Massachusetts Institute Of Technology | Circular RNA compositions and methods |
CA3160739A1 (en) | 2019-12-04 | 2021-06-10 | Brian Goodman | Circular rna compositions and methods |
US11285145B2 (en) | 2020-05-27 | 2022-03-29 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4 |
CA3200234A1 (en) | 2020-11-25 | 2022-06-02 | Daryl C. Drummond | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
TR202019788A1 (tr) * | 2020-12-05 | 2022-06-21 | Istanbul Medipol Ueniversitesi | SARS-CoV-2 ANA PROTEAZ ENZİMİNİN KATALİTİK AKTİVİTESİNİ İNHİBE EDEBİLEN KÜÇÜK TERAPÖTİK MOLEKÜLLER |
JP2024502270A (ja) | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬 |
CN114478525B (zh) * | 2022-03-28 | 2023-05-30 | 山东京博农化科技股份有限公司 | 一种四氢-β-咔啉吡唑酰胺衍生物及其制备方法和应用 |
WO2024076626A1 (en) * | 2022-10-05 | 2024-04-11 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
WO2024076633A1 (en) * | 2022-10-05 | 2024-04-11 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
CN116354959B (zh) * | 2023-03-10 | 2024-04-19 | 石河子大学 | 一种N-N桥连噻唑单元的β-咔啉衍生物及其制备方法、应用 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1055203A (en) | 1964-09-16 | 1967-01-18 | Ici Ltd | -ß-carboline derivatives, a process for their manufacture, and compositions containing them |
EP0357122A3 (en) | 1988-08-29 | 1991-10-23 | Duphar International Research B.V | Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties |
JPH03287586A (ja) | 1990-04-02 | 1991-12-18 | Taisho Pharmaceut Co Ltd | テトラヒドロ―β―カルボリン誘導体 |
FR2662940B1 (fr) | 1990-06-08 | 1994-10-14 | Roussel Uclaf | Utilisation de derives de la tetrahydro isoquinoleine pour la preparation de medicaments anti-tumoraux, application a titre de medicaments de derives de la tetrahydro isoquinoleine et produits derives de cette structure. |
JPH04275221A (ja) | 1991-03-01 | 1992-09-30 | Taisho Pharmaceut Co Ltd | 制癌効果増強剤 |
US5206377A (en) | 1991-12-05 | 1993-04-27 | Whitby Research, Inc. | Compounds useful as antiproliferative agents |
US5622960A (en) | 1992-04-14 | 1997-04-22 | The United States Of America As Represented By The Department Of Health And Human Services | Topoisomerase II inhibitors and therapeutic uses therefor |
US5500431A (en) | 1993-04-14 | 1996-03-19 | Eli Lilly And Company | Tetrahydro-β-carbolines |
EP0620222A3 (en) | 1993-04-14 | 1995-04-12 | Lilly Co Eli | Tetrahydro-beta-carbolines. |
US5403851A (en) | 1994-04-05 | 1995-04-04 | Interneuron Pharmaceuticals, Inc. | Substituted tryptamines, phenalkylamines and related compounds |
CN1113648C (zh) | 1996-04-04 | 2003-07-09 | 弗·哈夫曼-拉罗切有限公司 | 四氢-β-咔啉衍生物作为抗转移瘤剂的用途 |
FR2748026B1 (fr) | 1996-04-26 | 1998-06-05 | Adir | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO1998006719A1 (en) | 1996-08-09 | 1998-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | 4-substituted beta-carbolines as immunomodulators |
JP4275221B2 (ja) | 1998-07-06 | 2009-06-10 | リンテック株式会社 | 粘接着剤組成物および粘接着シート |
DE19915178A1 (de) | 1999-04-03 | 2000-10-05 | Univ Mainz Johannes Gutenberg | Hepatitis C Virus Zellkultursystem |
EP1347759B1 (en) | 2000-12-08 | 2005-06-29 | Smithkline Beecham Corporation | Antibacterial compounds |
US7022856B2 (en) | 2001-02-12 | 2006-04-04 | Lilly Icos Llc. | Carboline derivatives |
CA2437718C (en) | 2001-02-12 | 2010-03-16 | Lilly Icos Llc | Carboline derivatives |
WO2002078680A1 (de) | 2001-02-13 | 2002-10-10 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Gaba-rezeptor-modulatoren zur behandlung neurodegenerativer erkrankungen des auges |
US6720331B2 (en) | 2001-04-03 | 2004-04-13 | National Sun Yat-Sen University | 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents |
DE60236646D1 (de) * | 2001-04-13 | 2010-07-22 | Human Genome Sciences Inc | Anti-VEGF-2 Antikörper |
ATE469648T1 (de) | 2001-09-05 | 2010-06-15 | Minerva Biotechnologies Corp | Zusammensetzungen und deren verwendung zur behandlung von krebs |
JP2005508968A (ja) | 2001-10-19 | 2005-04-07 | トランス テック ファーマ,インコーポレイテッド | PTP阻害剤としてのβ−カルボリン誘導体 |
TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
CA2407755A1 (en) | 2002-10-11 | 2004-04-11 | The Hospital For Sick Children | Inhibition of vegf secretion |
EP1633751A1 (en) | 2003-06-16 | 2006-03-15 | Chroma Therapeutics Limited | Carboline and betacarboline derivatives for use as hdac enzyme inhibitors |
EA200600069A1 (ru) | 2003-06-20 | 2006-08-25 | Коли Фармасьютикал Гмбх | Низкомолекулярные антагонисты toll-подобных рецепторов (tlr) |
US7872133B2 (en) | 2003-06-23 | 2011-01-18 | Ono Pharmaceutical Co., Ltd. | Tricyclic heterocycle compound |
US20050101623A1 (en) | 2003-07-23 | 2005-05-12 | Pharmacia Corporation | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
AU2005206570A1 (en) | 2004-01-23 | 2005-08-04 | Novartis Vaccines And Diagnostics, Inc. | Tetrahydrocarboline compounds as anticancer agents |
US20080103213A1 (en) | 2004-03-05 | 2008-05-01 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of neurofibromatosis |
PL1737461T3 (pl) * | 2004-03-15 | 2013-05-31 | Ptc Therapeutics Inc | Pochodne karbolinowe użyteczne w hamowaniu angiogenezy |
WO2005089765A1 (en) | 2004-03-15 | 2005-09-29 | Howard James R | Enzyme cofactor combination for supplementing pyruvate dehydrogenase and alpha ketogluterate dehydrogenase complexes |
US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
FR2869540B1 (fr) | 2004-04-30 | 2008-05-16 | Centre Nat Rech Scient Cnrse | Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers |
EP1786519B1 (en) | 2004-05-19 | 2012-09-05 | Natural Source International | Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer |
MXPA06014421A (es) | 2004-06-10 | 2007-05-04 | Regeneron Pharma | Uso de inhibidores de vegf para el tratamiento de cancer humano. |
AU2005333126A1 (en) | 2004-07-18 | 2006-12-21 | Csl Limited | Methods and compositions for inducing innate immune responses |
JP2008508356A (ja) * | 2004-08-02 | 2008-03-21 | スミスクライン ビーチャム コーポレーション | Hpv感染に有用な化合物 |
WO2006065480A2 (en) | 2004-11-23 | 2006-06-22 | Ptc Therapeutics, Inc. | Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
WO2007002051A1 (en) * | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Carboline derivatives and their use as inhibitors of flaviviridae infections |
US7696227B2 (en) | 2007-04-13 | 2010-04-13 | Regents Of The University Of California | Small-molecule inhibitors of the androgen receptor |
WO2008127714A1 (en) | 2007-04-13 | 2008-10-23 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
EP2201972A1 (en) | 2008-12-23 | 2010-06-30 | Sanofi-Aventis Deutschland GmbH | Fixed dose injection device with resettable drive mechanism |
US20120157401A1 (en) | 2009-05-27 | 2012-06-21 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
US8703726B2 (en) | 2009-05-27 | 2014-04-22 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
WO2010138758A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
US20120157402A1 (en) | 2009-05-27 | 2012-06-21 | Liangxian Cao | Methods for treating brain tumors |
WO2010138706A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating breast cancer |
US8697662B2 (en) | 2009-05-27 | 2014-04-15 | Ptc Therapeutics, Inc. | Methods for treating Kaposi sarcoma |
US20130171103A1 (en) | 2010-05-27 | 2013-07-04 | Ptc Therapeutics, Inc. | Methods for treating viral conditions |
TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
JP2019001715A (ja) | 2015-10-30 | 2019-01-10 | 協和発酵キリン株式会社 | 三環性化合物 |
US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
EP3664803A4 (en) | 2017-08-01 | 2021-05-05 | PTC Therapeutics, Inc. | DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS |
CR20210093A (es) | 2018-08-03 | 2021-05-28 | Ptc Therapeutics Inc | Formas farmacéuticas orales biodisponibles |
-
2010
- 2010-05-27 WO PCT/US2010/036467 patent/WO2010138758A1/en active Application Filing
- 2010-05-27 TW TW105129635A patent/TWI671297B/zh active
- 2010-05-27 HU HUE10781238A patent/HUE052510T2/hu unknown
- 2010-05-27 CA CA3080983A patent/CA3080983C/en active Active
- 2010-05-27 CA CA2999345A patent/CA2999345A1/en not_active Abandoned
- 2010-05-27 MX MX2020005345A patent/MX2020005345A/es unknown
- 2010-05-27 MX MX2011012513A patent/MX348817B/es active IP Right Grant
- 2010-05-27 CN CN201610576145.5A patent/CN106167488A/zh active Pending
- 2010-05-27 US US13/321,257 patent/US9351964B2/en active Active
- 2010-05-27 CA CA2763485A patent/CA2763485C/en active Active
- 2010-05-27 ES ES10781238T patent/ES2826950T3/es active Active
- 2010-05-27 CA CA3184380A patent/CA3184380A1/en active Pending
- 2010-05-27 JP JP2012513266A patent/JP5898067B2/ja active Active
- 2010-05-27 EP EP10781238.0A patent/EP2434891B9/en active Active
- 2010-05-27 TW TW099117065A patent/TWI574961B/zh active
- 2010-05-27 PT PT107812380T patent/PT2434891T/pt unknown
- 2010-05-27 PL PL10781238T patent/PL2434891T3/pl unknown
- 2010-05-27 EP EP20176586.4A patent/EP3718405A1/en not_active Withdrawn
- 2010-05-27 CN CN2010800333584A patent/CN102480957A/zh active Pending
-
2015
- 2015-11-20 JP JP2015227314A patent/JP2016053078A/ja not_active Withdrawn
-
2016
- 2016-04-20 US US15/133,359 patent/US20160340354A1/en not_active Abandoned
- 2016-07-27 AU AU2016208323A patent/AU2016208323B2/en active Active
-
2018
- 2018-09-05 US US16/121,956 patent/US20190194188A1/en not_active Abandoned
-
2020
- 2020-06-23 US US16/909,394 patent/US11613538B2/en active Active
-
2023
- 2023-03-24 US US18/126,198 patent/US20240043422A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020005345A (es) | Un método para inhibir o reducir una infección viral por coronavirus. | |
AU2018201942B2 (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | |
PH12017502286A1 (en) | Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi) | |
PH12018500641A1 (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
EA200970953A1 (ru) | СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ | |
PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
WO2011112953A3 (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
MX2019008085A (es) | Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros. | |
MX336710B (es) | Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades. | |
MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
EP4140487A8 (en) | Combination therapy for treating cancer | |
MX2019000547A (es) | Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. | |
MX2011013424A (es) | Metodo de tratamiento del cancer con antagonista dll4 y agente quimioterapeutico. | |
WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
MX2010007887A (es) | Tratamiento y prevencion de condiciones cardiacas utilizando dos o mas isoformas del factor de crecimiento de hepatocitos. | |
MX2017014641A (es) | Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa). | |
MY169330A (en) | Method for inhibition of deubiquitinating activity | |
BR112013033544A2 (pt) | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos | |
WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
WO2008024844A3 (en) | Anticancer combination therapies | |
WO2011031890A3 (en) | Cancer stem cell-targeted and drug resistant cancer therapy | |
WO2011091154A3 (en) | Use of human erythrocytes for prevention and treatment of cancer dissemination and growth | |
WO2014018763A3 (en) | Method of treating type i diabetes using apolipoprotein aiv | |
WO2012106313A3 (en) | Ubiquitin interacting motif peptides as cancer therapeutics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |